Description: Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is based in Seongnam-si, South Korea.
Home Page: genomecom.co.kr
B-8F Silicon Park
Seongnam-si,
13486
South Korea
Phone:
82 3 1628 0150
Officers
| Name | Title |
|---|---|
| Mr. Jisoo Pae M.D. | Founder & CEO |
| Mr. Youngji Seo | Chief Executive Officer |
| Yoo Seok Hong | Chief Executive Officer |
| Mr. Hansoo Park | Founder & CTO |
| Mr. Sangkyun Kim | Chief Financial Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |